| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 9.4 | 11.8 |
| Profit before tax | -55.0 | -35.0 |
| Net income | -55.7 | -35.5 |
| EPS (diluted, $ a share) | $-1.63 | $-1.87 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -20.4% |
|---|
10-Q filed with the SEC, NASDAQ: NKTR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Nektar Therapeutics: key numbers
- Share price
- $35.91Close, Nov 17
- Market cap
- $1.23B
- Shares outstanding
- 34.21MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Nektar Therapeutics
All →Nektar Therapeutics Investor Meeting
Nektar Therapeutics reaffirmed its financial guidance, stating that its current cash and marketable securities balance of $952.9 million is expected to fund operations into the third quarter of 2028. This runway is intended to support the company through the initial Phase 3 data readouts for its ZENITH AD trials in atopic dermatitis, expected in the summer of 2028.
Nektar Therapeutics Financial Results
Nektar Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $952.9 million and the initiation of Phase 3 registrational trials for rezpegaldesleukin in atopic dermatitis. The company reported a net loss of $55.7 million on revenue of $9.4 million, with R&D expenses increasing to support its late-stage clinical programs.
- Term
- Q3 2026
“This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development. We have now initiated all three global ZENITH AD registrational trials in atopic dermatitis and our global ZENITH AA registrational trial in alopecia areata is on track to begin in December, earlier than previously planned.”
Howard Robin, President and Chief Executive Officer of Nektar
Nektar Therapeutics Clinical Trial Data
Nektar Therapeutics announced long-term Phase 2b data for rezpegaldesleukin in patients with alopecia areata (REZOLVE-AA) and atopic dermatitis (REZOLVE-AD) at the EADV Congress 2026. The data demonstrated sustained hair regrowth and deepening of response even six months after treatment cessation, suggesting a differentiated regulatory T cell (Treg) mechanism compared to existing systemic therapies.
- Earnings call
- Oct 1, 2026, 3:00 PM ET
Nektar Therapeutics Court & Legal Update
A jury in the U.S. District Court for the Northern District of California awarded Nektar Therapeutics $90 million in damages plus interest in its lawsuit against Eli Lilly. The jury found that Lilly breached the implied covenant of good faith and fair dealing regarding the license agreement for rezpegaldesleukin. The verdict remains subject to post-trial proceedings and potential appeals.
- Counterparty
- Eli Lilly and Company